CN Patent

CN106146583B — 新型胞苷衍生物及其应用

Assigned to Inner Mongolia Puyin Pharmaceutical Co ltd · Expires 2019-11-08 · 7y expired

What this patent protects

本发明公开了一种新型胞苷衍生物及其应用，具有下述通式(Ⅰ)： 本发明的新型胞苷衍生物对结肠癌HCT‑116荷瘤裸小鼠移植瘤的生长抑制试验证实，本发明的化合物的抗肿瘤活性高，同时对人结肠癌HCT‑116荷瘤小鼠体重的影响以及死亡率数据证明化合物的毒性较低。

USPTO Abstract

本发明公开了一种新型胞苷衍生物及其应用，具有下述通式(Ⅰ)： 本发明的新型胞苷衍生物对结肠癌HCT‑116荷瘤裸小鼠移植瘤的生长抑制试验证实，本发明的化合物的抗肿瘤活性高，同时对人结肠癌HCT‑116荷瘤小鼠体重的影响以及死亡率数据证明化合物的毒性较低。

Drugs covered by this patent

Patent Metadata

Patent number
CN106146583B
Jurisdiction
CN
Classification
—
Expires
2019-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Inner Mongolia Puyin Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.